Skip to main content

Aceragen, Inc.

ACGNDelisted Aug 16, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000861838

Aceragen, Inc. was delisted on Aug 16, 2023; its insiders filed their last Form 4 on Aug 11, 2023; 20 institutions reported holding it in 13F filings for Q2 2023, worth $269.5K in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding Aceragen, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of ACGN: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders5748−9
Shares9.83M6.34M−3.49M (−35.5%)
Value$12.8M$7.60M−$5.17M (−40.5%)

New holders (9)

Institutions that held Aceragen, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to ACGN in Q2 2021
InstitutionSharesValue% of portfolio
Marshall Wace, LLP477,449$573.0K0.00%
Clear Creek Financial Management, LLC49,696$60.0K0.01%
Goldman Sachs Group Inc25,976$31.0K0.00%
Manufacturers Life Insurance Company, The13,933$17.0K0.00%
Jane Street Group, LLC13,006$15.0K0.00%
People's United Financial, Inc.11,660$14.0K0.00%
Cutler Group LP5,100$6.00K0.00%
JPMorgan Chase & Co481$1.00K0.00%
Parallel Advisors, LLC1,000$1.00K0.00%

Sold out (18)

Institutions that held Aceragen, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.